[go: up one dir, main page]

PE20251537A1 - Compuestos de indolinilo antivirales y usos de estos - Google Patents

Compuestos de indolinilo antivirales y usos de estos

Info

Publication number
PE20251537A1
PE20251537A1 PE2024002633A PE2024002633A PE20251537A1 PE 20251537 A1 PE20251537 A1 PE 20251537A1 PE 2024002633 A PE2024002633 A PE 2024002633A PE 2024002633 A PE2024002633 A PE 2024002633A PE 20251537 A1 PE20251537 A1 PE 20251537A1
Authority
PE
Peru
Prior art keywords
independently
alkyl
haloalkyl
pharmaceutically acceptable
compounds
Prior art date
Application number
PE2024002633A
Other languages
English (en)
Inventor
Aesop Cho
La Fuente Katherine De
Thomas P Stratton
Peiyuan Wang
William J Watkins
Jie Xu
Kin S Yang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20251537A1 publication Critical patent/PE20251537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a compuestos de indolinilo de formula (I) o una sal aceptable desde el punto de vista farmaceutico de este. En la formula (I), cada uno de R2a, R2b, R2c, R3a, R3b, R4a, R4b, y R4c son independientemente H, halogeno, C1-6 alquilo, entre otros; cada uno de Xa y Xb son independientemente O o CR7aR7b; cada uno de R7a y R7b son independientemente H, C1-6 alquilo o C1-6 haloalquilo, entre otros; R5 es C6-10 arilo o heteroarilo, opcionalmente sustituido con de uno a tres Z5, que pueden ser iguales o diferentes, en donde el heteroarilo tiene de 5 a 10 miembros con uno a tres heteroatomos, donde cada uno es independientemente N, O o S; R6 es H, C1-6 alquilo, C1-6 haloalquilo, C2-8 alcoxialquilo o C3-6 cicloalquilo, en donde el cicloalquilo de R6 esta opcionalmente sustituido con de uno a tres Z6; y, Z5 y Z6 son independientemente -CN, C1-6alquilo, C1-6 haloalquilo, entre otros. Tambien se refiere a una composicion farmaceutica que comprende el compuesto, o una sal aceptable desde el punto de vista farmaceutico de este, y al menos un portador aceptable desde el punto de vista farmaceutico; y, adicionalmente uno, dos, tres o cuatro agentes terapeuticos. Dichos compuestos o composicion farmaceutica permiten el tratamiento de enfermedades y/o afecciones mediante la inhibicion de la helicasa-primasa viral, asi como infecciones virales.
PE2024002633A 2022-05-20 2023-05-18 Compuestos de indolinilo antivirales y usos de estos PE20251537A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263344487P 2022-05-20 2022-05-20
PCT/US2023/022679 WO2023225162A1 (en) 2022-05-20 2023-05-18 Antiviral indolinyl compounds and uses thereof

Publications (1)

Publication Number Publication Date
PE20251537A1 true PE20251537A1 (es) 2025-06-05

Family

ID=86851818

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002633A PE20251537A1 (es) 2022-05-20 2023-05-18 Compuestos de indolinilo antivirales y usos de estos

Country Status (16)

Country Link
US (1) US12522582B2 (es)
EP (1) EP4526289A1 (es)
JP (1) JP2025517423A (es)
KR (1) KR20250016217A (es)
CN (1) CN119546574A (es)
AR (1) AR129378A1 (es)
AU (1) AU2023272886A1 (es)
CA (1) CA3255969A1 (es)
CL (1) CL2024003512A1 (es)
CO (1) CO2024016912A2 (es)
DO (1) DOP2024000243A (es)
IL (1) IL317009A (es)
MX (1) MX2024014346A (es)
PE (1) PE20251537A1 (es)
TW (2) TW202502324A (es)
WO (1) WO2023225162A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104687A1 (en) 2023-11-17 2025-05-22 Gilead Sciences, Inc. Solid forms of a hsv helicase primase inhibitor
TW202540079A (zh) * 2023-11-17 2025-10-16 美商基利科學股份有限公司 抗病毒吲哚啉基化合物及其用途
WO2025172927A1 (en) 2024-02-16 2025-08-21 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2026015762A1 (en) 2024-07-12 2026-01-15 Gilead Sciences, Inc. (r)-5-fluoro-2-methyl-1-((r)-5-(pyridin-2-yl)-2,3-dihydro-1 h-indene-2-carbonyl)indoline-6-sulfonamide for treatment of viral infections unresponsive to treatment with a first antiviral therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
JP6237779B2 (ja) 2012-11-03 2017-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害薬
WO2018127207A1 (zh) 2017-01-09 2018-07-12 南京明德新药研发股份有限公司 噻唑衍生物及其应用
EP3819297B1 (en) 2018-07-06 2024-04-03 Phaeno Therapeutics Co., Ltd. Crystal forms of thiazole compound and application thereof
US20230066268A1 (en) 2019-12-18 2023-03-02 Merck Sharp & Dohme Llc Indazole derivatives and methods of use thereof for the treatment of herpes viruses

Also Published As

Publication number Publication date
AU2023272886A1 (en) 2024-12-05
CO2024016912A2 (es) 2024-12-19
MX2024014346A (es) 2025-02-10
KR20250016217A (ko) 2025-02-03
TWI859869B (zh) 2024-10-21
WO2023225162A1 (en) 2023-11-23
DOP2024000243A (es) 2025-05-15
US12522582B2 (en) 2026-01-13
TW202402270A (zh) 2024-01-16
EP4526289A1 (en) 2025-03-26
JP2025517423A (ja) 2025-06-05
AR129378A1 (es) 2024-08-21
CN119546574A (zh) 2025-02-28
CA3255969A1 (en) 2023-11-23
IL317009A (en) 2025-01-01
US20240101529A1 (en) 2024-03-28
CL2024003512A1 (es) 2025-05-02
TW202502324A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
PE20251537A1 (es) Compuestos de indolinilo antivirales y usos de estos
CO2023018119A2 (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
ES2566973T3 (es) Uso de SNS-595 para tratar leucemia
PE20210003A1 (es) Compuestos de purinona y su uso en el tratamiento del cancer
PE20211655A1 (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
CL2022003326A1 (es) Compuestos de 4-oxo-3,4-dihidroquinazolinón para el tratamiento de las enfermedades y trastornos asociados a braf
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
NO20074619L (no) Spiro-oksindolforbindelser og deres anvendelse som medikamenter
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
SG159561A1 (en) Thiazole compounds and methods of use
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
AR081261A1 (es) Metodos para tratar afecciones virales
DOP2013000238A (es) Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
PE20151332A1 (es) Compuestos de azabencimidazol
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CR20190147A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
ECSP21067189A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
PE20080355A1 (es) Compuestos peptidicos como inhibidores de proteasa de serina del virus de hepatitis c
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
PE20220252A1 (es) Compuestos de pirrol
PE20251387A1 (es) Moduladores de bcl6 como degradadores dirigidos por ligando
CR20230008A (es) Metil (r)-2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h-ciclopenta[b]piridin-3-carboxilato y metil (r)-2-(fluorometil)-5-oxo-4-fenil-1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilato como activadores de cav1.2